Novartis to Provide Cholesterol-Fighting Drug Leqvio in UK
01 Setembro 2021 - 02:36AM
Dow Jones News
By Joshua Kirby
Novartis AG has reached a deal to provide its
cholesterol-lowering medicine Leqvio to patients via the U.K.'s
National Health Service, the Swiss pharmaceutical company said
Wednesday.
Over the course of three years, around 300,000 patients should
be treated with Leqvio (inclisiran), Novartis said. The patients
targeted are those at high risk of having a second cardiovascular
event.
The treatment is part of a population health-management approach
and aims to reduce patients' long-term elevated LDL cholesterol, a
key modifiable risk factor in cardiovascular disease, the company
said.
The collaboration with the NHS follows final recommendation for
Leqvio from the U.K.'s medicines regulator, NICE.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
September 01, 2021 01:21 ET (05:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024